• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

Adoptive immunotherapy causes tumor regression in melanoma patients

France - Melanoma patients treated with a special tumor-fighting T cell have a greater change of survival without relapse, according to HealthDay News.

France - Melanoma patients treated with a special tumor-fighting T cell have a greater change of survival without relapse, according to HealthDay News.

The French research team used a process in which natural cancer-fighting T cells are removed from the tumor of a patient with late stage melanoma. The T cells are put in culture dishes to expand in number, before being re-infused into the patient, according to a study published online in the Journal of Experimental Medicine.

The therapy caused tumor regression in about half the patients treated, some of whom remained tumor-free for more than a decade. Researchers say those without relapse had naturally arising T cells in their systems that recognized the protein meloe-1, which is highly expressed in melanoma cells but not in normal cells.

Meloe-1 specific T cells were found in five of the nine relapse-free patients and none of the 21 patients that did relapse, according to HealthDay.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.